The scientific magazine “Anti-cancer drugs” i has published the results of the Y-IMAGE Phase IV study .
In real-life, Yondelis® improves the results obtained in previous clinical trials in soft tissue sarcoma.
Yondelis® provides in this observational study (Y-IMAGE) in the treatment of soft tissue sarcoma, an overall survival of 21.3 months, this being higher that the 13.5 months observed in a recently approved compound for this indication .
With regards to progression free survival, in this study Yondelis® reached 5.9 months improving the 4.6 months of another recently approved drug for this indication .